EIA
ABBV icon

Emerald Investment Advisers’s AbbVie ABBV Stock Holding History

Emerald Investment Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5M Buy
45,889
+8,188
+22% +$1.76M 0.77% 30
2026
Q1 		$8.2M Buy
+37,701
New +$8.36M 0.74% 29

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Emerald Investment Advisers's ABBV Position: Q2 2026 in Review

Emerald Investment Advisers increased its AbbVie (ABBV) stake by 22% in Q2 2026, buying an estimated $1.76M and bringing the position to 45,889 shares worth $11.5M. The position accounts for 0.77% of the portfolio, ranked #30.

Emerald Investment Advisers first reported a position in ABBV in Q1 2026 and has held it in 2 quarters since. 4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Emerald Investment Advisers held 45,889 shares of AbbVie worth $11.5M as of Q2 2026.
  • Emerald Investment Advisers bought 8,188 AbbVie shares in Q2 2026, an estimated $1.76M.
  • AbbVie made up 0.77% of Emerald Investment Advisers's portfolio in Q2 2026, its #30 holding.
  • Emerald Investment Advisers first reported a position in AbbVie in Q1 2026 and has held it in 2 quarters since.
  • 4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Emerald Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.